Search results for "HIV-1"

showing 10 items of 177 documents

The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects

2017

Altered interactions between the gut mucosa and bacteria during HIV infection seem to contribute to chronic immune dysfunction. A deeper understanding of how nutritional interventions could ameliorate gut dysbiosis is needed. Forty-four subjects, including 12 HIV+ viremic untreated (VU) patients, 23 antiretroviral therapy-treated (ART(+)) virally suppressed patients (15 immunological responders and 8 non-responders) and 9 HIV- controls (HIV-), were blindly randomized to receive either prebiotics (scGOS/lcFOS/glutamine) or placebo (34/10) over 6 weeks in this pilot study. We assessed fecal microbiota composition using deep 16S rRNA gene sequencing and several immunological and genetic marker…

AdultMale0301 basic medicine030106 microbiologyImmunologyHIV InfectionsInflammationButyrateBiologyGut floraMicrobiologyFeces03 medical and health sciencesIntestinal mucosaImmunityRNA Ribosomal 16SmedicineHumansImmunology and AllergyIntestinal MucosaBacteriaImmunityMiddle AgedPlacebo Effectmedicine.diseasebiology.organism_classificationGastrointestinal MicrobiomeGlutamineButyratesPrebiotics030104 developmental biologyMucosal immunologyDietary SupplementsHost-Pathogen InteractionsImmunologyHIV-1DysbiosisFemalemedicine.symptomDysbiosisMucosal Immunology
researchProduct

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 …

2020

Our aim was to evaluate the association between recent eGFR values and risk of switching from TDF to TAF or dual therapy (DT) in real life. HIV-positive patients achieving HIV-RNA ≤50 copies/mL for the first time after starting a TDF-based regimen were included. Kaplan–Meier (KM) curves and Cox regression models were used to estimate the time from TDF to switch to TAF or DT. 1486 participants were included: median (IQR) age 36 (30–42) years; baseline CKD-EPI eGFR 99.92 (86.47–111.4) mL/min/1.73m2. We observed a consistently higher proportion of people with HIV-RNA ≤50 copies/mL who switched from TDF to TAF rather than to DT. By competing risk analysis, at 2 years from baseline, the probabil…

AdultMale0301 basic medicineMicrobiology (medical)Dual therapymedicine.medical_specialtyTenofovirAnti-HIV Agents030106 microbiologyUrologyRenal functionTenofovir alafenamide03 medical and health sciences0302 clinical medicineHiv infectedeGFRmedicineHumansPharmacology (medical)Prospective StudiesTenofovir alafenamide030212 general & internal medicineDual therapyTenofovirAcquired Immunodeficiency SyndromeAlanineDrug SubstitutionProportional hazards modelbusiness.industryAdenineHIVGeneral MedicineViral LoadAntiretroviral therapyRegimenInfectious DiseasesHIV-1Drug Therapy CombinationFemaleTenofovir disoproxil fumarate.businessViral loadGlomerular Filtration Ratemedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma.

2006

BACKGROUND Classic Kaposi sarcoma (CKS) is an inflammatory-mediated neoplasm that develops in the presence of KS-associated herpesvirus (KSHV) and immune perturbation. In the current study, the authors compared CKS cases with age-matched and sex-matched KSHV-seropositive controls without human immunodeficiency virus-1 infection and markers of viral control, blood counts, CD4-positive and CD8-positive lymphocytes, and serum β-2-microglobulin and neopterin levels. METHODS Viral loads were detected using real-time amplification of the KSHV-K6 and EBV-pol genes, anti-K8.1 (lytic) titers were detected by enzyme-linked immunoadsorbent assay, and antilatent nuclear antigen (LANA) titers were detec…

AdultMaleCancer ResearchHIV InfectionsHematocritmedicine.disease_causePeripheral blood mononuclear cellHerpesviridaechemistry.chemical_compoundAntigenRisk FactorsmedicineGammaherpesvirinaeHumansSarcoma KaposiAgedAged 80 and overmedicine.diagnostic_testbiologybusiness.industryAntibody titerNeopterinMiddle Agedbiology.organism_classificationKaposi Sarcoma human herpesvirus-8 immunityOncologychemistryItalyImmunologyMultivariate AnalysisDisease ProgressionHIV-1FemalebusinessViral loadBiomarkersCancer
researchProduct

Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end-organ disease

1998

Human cytomegalovirus (HCMV)-specific antibody responses in HIV-1 infected individuals either with or without HCMV end-organ disease were examined to determine the whether development of HCMV disease was associated with a particular deficit in the antibody response. Antiwhole HCMV, anti-glycoprotein B (gB), and neutralizing antibody levels were higher in HIV-1 infected individuals than in healthy immunocompetent subjects, particularly in patients with AIDS either with or without HCMV-associated disease. Irrespective of location and spread of HCMV disease, patients who had received anti-HCMV therapy prior to sampling exhibited significantly higher anti-gB and neutralizing antibody titers tha…

AdultMaleHuman cytomegalovirusAdolescentvirusesCytomegalovirusBiologyAntibodies ViralAntiviral AgentsViral Envelope ProteinsNeutralization TestsBetaherpesvirinaeVirologyImmunopathologymedicineHumansViremiaFluorescent Antibody Technique IndirectNeutralizing antibodyAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic InfectionsAntibody titervirus diseasesbiochemical phenomena metabolism and nutritionmedicine.diseasebiology.organism_classificationVirologyCD4 Lymphocyte CountInfectious DiseasesImmunoglobulin GCytomegalovirus InfectionsImmunologyHIV-1biology.proteinFemaleViral diseaseAntibodyViral loadJournal of Medical Virology
researchProduct

Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Stu…

2016

International audience;  Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce.  A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of 100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme.

AdultMaleHuman immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeVirusSerology03 medical and health sciences0302 clinical medicineImmunogenicity Vaccine[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyAntiretroviral Therapy Highly ActiveHepatitis B virus HBVImmunology and AllergyMedicineHumansHepatitis B Vaccines030212 general & internal medicineProspective StudiesHepatitis B AntibodiesProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyVaccines Syntheticbiologybusiness.industryImmunogenicityvirus diseasesMiddle AgedHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesVaccinationInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyImmunologybiology.proteinHIV-1030211 gastroenterology & hepatologyFemaleAntibodybusiness
researchProduct

Dynamics and molecular evolution of HIV-1 strains in Sicily among antiretroviral naïve patients.

2012

Abstract HIV-1 subtype B is the most frequent strain in Sicily. To date, there is no available data about the genetic diversity of HIV-1 viral strains circulating in Sicily among antiretroviral (ARV) naive subjects and the role of immigration as potential determinant of evolutionary dynamics of HIV-1 molecular epidemiology. For this purpose, HIV-1 polymerase (pol) sequences obtained from 155 ARV naive individuals from 2004 to 2009 were phylogenetically analysed. The overall rate of HIV-1 non-B infections was 31.0% (n = 48/155), increasing from 7.8% in 2004–2006 to 40.9% in 2009, and about one-third were identified as unique recombinant forms. CRF02_AG was the prevalent non-B clade (n = 28/4…

AdultMaleMicrobiology (medical)AdolescentPopulationHIV Infectionsnon-B subtypeBiologySettore MED/42 - Igiene Generale E ApplicataMicrobiologyCohort StudiesEvolution MolecularMolecular evolutionGeneticsCluster AnalysisHumansHIV-1 subtypes; non-B subtypes; CRF; Molecular evolution; HAART-naïve patientsChildEvolutionary dynamicseducationCladeSicilyMolecular BiologyPhylogenyEcology Evolution Behavior and SystematicsAgedMolecular Epidemiologyeducation.field_of_studyGenetic diversityHIV-1 subtypeChi-Square DistributionMolecular epidemiologyPhylogenetic treeHAART-naïve patientsStrain (biology)Infantvirus diseasesCRFMiddle AgedGenes polVirologyInfectious DiseasesChild PreschoolHIV-1Molecular evolutionFemale
researchProduct

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

2012

Prevalence and predictors of transmitted drug resistance (TDR), defined as the presence of at least one WHO surveillance drug resistance mutation (SDRM), were investigated in antiretroviral-naïve HIV-1-infected patients, with a genotypic resistance test (GRT) performed ≤6months before starting cART between 2000 and 2010. 3163 HIV-1 sequences were selected (69% subtype B). Overall, the prevalence of TDR was 12% (13.2% subtype B, 9% non-B). TDR significantly declined overall and for the single drug classes. Older age independently predicted increased odds of TDR, whereas a more recent GRT, a higher HIV-RNA and C vs. B subtype predicted lower odds of TDR. © 2012 The Authors. Clinical Microbiol…

AdultMaleMicrobiology (medical)CartDrugmedicine.medical_specialtyGenotypeAnti-HIV Agentsmedia_common.quotation_subjectHuman immunodeficiency virus (HIV)HIV InfectionsDrug resistancemedicine.disease_causeArticleEvolution Molecular03 medical and health sciencesrecent HIV infection0302 clinical medicineInternal medicineDrug Resistance ViralPrevalencemedicineHumansHIV Infection030212 general & internal medicinemedia_common0303 health scienceschronic HIV infection030306 microbiologybusiness.industryAntiretroviral therapy; Chronic HIV infection; Recent HIV infection; Resistance epidemiology; Transmitted resistance; Microbiology (medical); Infectious DiseasesAnti-HIV AgentGeneral MedicineMiddle Agedtransmitted resistanceVirologyAntiretroviral therapy3. Good healthAntiretroviral therapyInfectious DiseasesItalyHIV-1Genotypic resistanceFemalebusinessHumanresistance epidemiologyClinical Microbiology and Infection
researchProduct

Role of PCR in Diagnosis and Prognosis of Visceral Leishmaniasis in Patients Coinfected with Human Immunodeficiency Virus Type 1

2001

ABSTRACT A group of 76 consecutive human immunodeficiency virus (HIV)-positive patients with fever of unknown origin ( n = 52) or fever associated with pulmonary diseases was evaluated in order to assess the usefulness of PCR with peripheral blood in the diagnosis and follow-up of visceral leishmaniasis. We identified 10 cases of visceral leishmaniasis among the 52 patients with fever of unknown origin. At the time of diagnosis, all were parasitemic by PCR with peripheral blood. During follow-up, a progressive decline in parasitemia was observed under therapy, and all patients became PCR negative after a median of 5 weeks (range, 6 to 21 weeks). However, in eight of nine patients monitored …

AdultMaleMicrobiology (medical)Settore MED/17 - Malattie InfettiveLeishmania donovaniHIV InfectionsParasitemiaPolymerase Chain ReactionImmunopathologymedicineAnimalsHumansLeishmania infantumFever of unknown originbiologyLeishmaniasisDNA ProtozoanMiddle AgedPrognosisvisceral leishmaniasis; HIV; PCR diagnosisSettore MED/07 - Microbiologia e Microbiologia Clinicabiology.organism_classificationmedicine.diseaseVisceral leishmaniasisImmunologyHIV-1Leishmaniasis VisceralFemaleParasitologyViral diseaseLeishmania infantumPolymorphism Restriction Fragment LengthLeishmania donovaniJournal of Clinical Microbiology
researchProduct

Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines…

2006

ABSTRACTThis study aimed to determine the effect of highly active anti-retroviral therapy (HAART) and hepatitis C virus (HCV) co-infection on peripheral levels of interleukin (IL)-2, IL-10, IL-12 (p70), IL-18 and soluble tumour necrosis factor receptor type II (sTNFRII). Serum levels were monitored for a 1-year period in 25 patients infected with human immunodeficiency virus-1 (HIV-1) who were naive for HAART at the initiation of the study, and in four HIV-1-infected long-term non-progressors. Serum levels of both IL-18 and sTNFRII at baseline were significantly higher in HIV-1-infected patients than in controls. Baseline levels of IL-18 and sTNFRII were not significantly different in long-…

AdultMaleMicrobiology (medical)hepatitis C virusTime FactorsHAARTHepatitis C virusHepacivirusHIV Infectionsmedicine.disease_causeserum cytokinesReceptors Tumor Necrosis FactorVirusEtanerceptAntiretroviral Therapy Highly ActiveImmunopathologymedicineHumansLongitudinal StudiesDemographybiologyhuman immunodeficiency virusbusiness.industryInterleukinsInterleukinvirus diseasesGeneral MedicineHepatitis Csoluble tumour necrosis factor receptor type IIMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CInfectious DiseasesImmunoglobulin GImmunologyLentivirusHIV-1CytokinesFemaleViral diseasebusinessIL-18Clinical Microbiology and Infection
researchProduct

Extremely High Mutation Rate of HIV-1 In Vivo.

2015

Rates of spontaneous mutation critically determine the genetic diversity and evolution of RNA viruses. Although these rates have been characterized in vitro and in cell culture models, they have seldom been determined in vivo for human viruses. Here, we use the intrapatient frequency of premature stop codons to quantify the HIV-1 genome-wide rate of spontaneous mutation in DNA sequences from peripheral blood mononuclear cells. This reveals an extremely high mutation rate of (4.1 ± 1.7) × 10−3 per base per cell, the highest reported for any biological entity. Sequencing of plasma-derived sequences yielded a mutation frequency 44 times lower, indicating that a large fraction of viral genomes …

AdultMaleMutation rateSequence analysisQH301-705.5Nonsense mutationHIV InfectionsBiologyGeneral Biochemistry Genetics and Molecular BiologyYoung AdultMutation RateHumansMutation frequencyBiology (General)GeneticsGeneral Immunology and MicrobiologySequence Analysis RNAGeneral NeuroscienceMiddle AgedVirologyReverse transcriptaseStop codon3. Good healthMutation (genetic algorithm)Disease ProgressionSynopsisHIV-1FemaleGeneral Agricultural and Biological SciencesViral loadResearch ArticlePLoS Biology
researchProduct